Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

InflaRx's strategy targets the C5a pathway, implicated in many inflammatory conditions. By focusing on this single mechanism, their drug could potentially treat a wide range of diseases, from skin conditions to kidney disease, effectively creating a valuable "pipeline in a drug."

Injecting a genetic medicine into one tumor can trigger an 'abscopal response,' where the immune system learns to recognize the cancer. This educated immune system then travels throughout the body to find and destroy other metastatic tumors, even those in deep organs like the lungs, which are typically the fatal ones.

Successful immunotherapies like anti-PD-1 work by shifting the battlefield's arithmetic. They enhance the efficiency of each T-cell, allowing one cell to destroy five or ten cancer cells instead of three. This turns the fight into a 'numbers game' that the immune system can finally win.

Instead of complex ex-vivo cell engineering, Zag Bio's antibody platform programs the body's own thymus to produce long-lived, antigen-specific regulatory T-cells. This approach simplifies the therapeutic process by turning the organ into a drug-producing factory.

CAR-T cells are engineered to recognize a single antigen, which tumors can downregulate to escape. In contrast, TIL therapy uses a patient's own T-cells that naturally recognize multiple tumor antigens. This polyclonal attack creates a higher barrier for the cancer to develop resistance compared to a single-target CAR-T therapy.